News
News
Description of service
This TNA is for production of GMP compliant starting material (pre-GMP seed stock, i.e. seed stock suitable for large scale GMP production). The VVCF will produce MVA vector(s) expressing antigen(s) of interest to the accessor, with appropriate QC. Vector design, for example insert size, expression of multiple antigens, will be discussed.
Timeline
1 viral vectored vaccine (GMP compliant), MVA approx. 6 months.
Services do NOT include
Additional QC e.g. mycoplasma testing unless requested (all services to be discussed at the start of the project).
Sample Requirements - input of users
DNA encoding the antigen(s), and DNA sequence data. Function of the antigen and potential pathogenicity. Prior experience expressing antigen, e.g. relevant publications. Any other relevant information e.g. expressed as trimer, is secreted/has transmembrane domain, is glycosylated.
Lead Scientist
Professor Adrian Hill
Production of pre-GMP grade MVA vector(s) expressing antigen(s) of interest
Free
Possible Output
To be discussed with user: For MVA, markerless virus potentially suitable for transfer to GMP manufacturing organisation (frozen in aliquots, with QC data: titre in pfu, sterility and identity/purity assessed by PCR and final virus sequencing).